FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology. Invention represents a method for preparing the original vaccine strain and a method for specific prevention of pulmonary tuberculosis by means of a mucosal vector vaccine based thereon. Vaccine strain A/PR8-NS124-TB10.4-2A-HspX is produced on the basis of influenza virus with shortened NS1 protein and heterologous insert coding full-size antigens TV10.4 and HspX M.tuberculosis.
EFFECT: routine of preventive prime-immunization, involving primary BCG immunization and boosting intranasal immunization with an original vector vaccine based on strain A/PR8/NS124-TB10_4-2A-HspX, provides a protective effect substantially exceeding the protective effect of the BCG vaccine on the main indicators of the severity of the tuberculous infection.
2 cl, 8 dwg, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RECOMBINANT STRAIN OF A/PR8-NS124-Luc INFLUENZA VIRUS AND METHOD FOR EVALUATING POST-VACCINAL NEUTRALIZING ANTIBODIES USING BIOLUMINESCENT DETECTION | 2019 |
|
RU2759054C2 |
| RECOMBINANT INFLUENZA VIRUS INTENDED FOR THE PREVENTION OF COVID-19 AND INFLUENZA, METHOD OF ITS PRODUCTION AND USE | 2022 |
|
RU2802058C1 |
| RECOMBINANT INFLUENZA VIRUS STRAIN A/PR8/HK-NS80E85A, EXPRESSING FRAGMENTS OF ESAT-6 AND AG85A MYCOBACTERIUM TUBERCULOSIS ANTIGENS, TO OBTAIN TUBERCULOSIS VECTORED VACCINE | 2018 |
|
RU2678175C1 |
| FMDV RECOMBINANT VACCINES AND USE THEREOF | 2015 |
|
RU2745373C2 |
| CHIMERIC VACCINES BASED ON VIRUSES OF FLAVIVIRUS AND LYSSAVIRUS GENES | 2019 |
|
RU2816136C2 |
| COMBINATION THERAPY FOR CANCER TREATMENT USING RECOMBINANT MVA AND ANTIBODIES INTRODUCED INTRAVENOUSLY | 2018 |
|
RU2795103C2 |
| INFLUENZA VIRUS STRAIN A/Hongkong/1/68/162/35 (H3N2) - UNIVERSAL DONOR OF INTERNAL GENES FOR REASSORTANTS, AND REASSORTANT STRAINS A/SPB/GK/09 (H1N1) AND A/HK/Astana/6:2/2010 (H5N1) PREPARED THEREOF | 2011 |
|
RU2511431C2 |
| RECOMBINANT VACCINE STRAIN FOR LIVE INTRANASAL VACCINE PROVIDING COMBINED PREVENTION OF INFLUENZA AND CORONAVIRUS INFECTIONS | 2022 |
|
RU2782531C1 |
| VACCINES BASED ON VIRUS-LIKE PARTICLES (VLP) OF CANINE PARVOVIRUS (CPV) AND APPLICATION THEREOF | 2016 |
|
RU2710854C1 |
| VACCINE AGAINST FELINE LEUKEMIA VIRUS | 2018 |
|
RU2784533C2 |
